Arrowhead Pharmaceuticals, Inc.
ARWR
$65.00
-$0.08-0.12%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -1.63M | -148.42M | -143.97M | -639.71M | -599.49M |
| Total Depreciation and Amortization | 23.93M | 22.57M | 21.13M | 19.57M | 18.60M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 175.49M | 119.62M | 113.31M | 100.34M | 92.96M |
| Change in Net Operating Assets | -18.24M | 28.08M | 70.68M | 28.52M | 25.09M |
| Cash from Operations | 179.55M | 21.85M | 61.15M | -491.28M | -462.85M |
| Capital Expenditure | -22.67M | -39.47M | -51.55M | -80.33M | -141.47M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -106.63M | -385.37M | -507.73M | -327.67M | -278.60M |
| Cash from Investing | -129.29M | -424.84M | -559.28M | -408.00M | -420.07M |
| Total Debt Issued | 10.26M | 399.10M | 392.00M | 392.00M | 392.00M |
| Total Debt Repaid | -201.63M | -201.63M | -151.63M | -- | -- |
| Issuance of Common Stock | 245.37M | 245.09M | 245.25M | 432.02M | 431.65M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 20.00M | 16.87M | 66.87M | 66.87M | 46.87M |
| Cash from Financing | 74.01M | 459.43M | 552.49M | 890.89M | 870.52M |
| Foreign Exchange rate Adjustments | -401.00K | 3.96M | 3.64M | 4.07M | 4.20M |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 123.86M | 60.39M | 58.01M | -4.33M | -8.21M |